JAK2 and vasculitis: Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events.<h4>Conclusion</h4>This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with <i>JAK2</i> mutation-positive ET.